Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • pharmaceutical industry

    - PMLiVE

    Lilly and MeiraGTx partner in $475m ophthalmology deal

    The companies will develop and commercialise therapies for genetic conditions

    The (clinical) trials and tribulations of gene therapy – why meaningful patient engagement strategies matter

    By Sarah Mohamad and Lauren Coleman-Bennett

    Amiculum

    What do people look for in gene therapy materials? Results from our survey of patients and relatives

    By Sam Fraser

    Amiculum

    - PMLiVE

    CSL Behring announces four-year results for haemophilia B gene therapy Hemgenix

    The genetic bleeding disorder affects an estimated one per every 19,283 male births in the US

    - PMLiVE

    NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

    About 15,000 people in England are living with the inherited blood disorder

    - PMLiVE

    Vertex and Orum partner on gene editing conditioning drugs in deal worth $945m

    The agreement gives Vertex the rights to use Orum’s targeted protein degradation technology

    - PMLiVE

    Free Live Webinar – Uniting Communities for Rare Disease Clinical Trial Success

    Join this live webinar focusing on patient recruitment and retention in rare disease trials.

    Innovative Trials

    - PMLiVE

    ABPI publishes new prescribing support guide for healthcare professionals

    The report will help pharmaceutical companies support high-quality healthcare

    - PMLiVE

    FDA publishes final industry guidance for CAR-T and gene therapies

    The new guidance can also be applied to other genetically modified lymphocyte products, including  CAR NK cells

    - PMLiVE

    New terms for UK medicines scheme send ‘mixed message’ to life sciences industry

    Life sciences leaders have previously warned against changes to the statutory scheme

    - PMLiVE

    NHS and pharmaceutical industry partnerships to change millions of lives

    The report highlights how UK ICSs and the pharmaceutical industry can work together

    - PMLiVE

    AstraZeneca and Cellectis enter gene therapy partnership worth over $2.2bn

    The deal gives AZ access to Cellectis’ gene editing technologies and manufacturing capabilities

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links